Histone demethylase inhibitors
The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted 3-aminopyridine derivative compounds, substituted 3-aminopyridazine derivative compounds, and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof,
wherein,
X is O or NR 5 ;
R 1 is hydrogen or alkyl;
each R 3 is independently selected from hydroxy, halogen, cyano, NH 2 , NHR 4 , N(R 4 ) 2 , NHC(O)R 4 , NHC(O)OR 4 , NHC(O)NHR 4 , NHC(O)N(R 4 ) 2 , NHS(O) 2 R 4 , NR 4 C(O)R 4 , NR 4 C(O)OR 4 , NR 4 C(O)NHR 4 , NR 4 C(O)N(R 4 ) 2 , NR 4 S(O) 2 R 4 , alkyl, alkenyl, alkynyl, alkoxy, aryl, aryloxy, aralkyl, carbocyclyl, heterocyclyl, heteroaryl, carbocyclylalkyl, heterocyclylalkyl, or heteroarylalkyl;
each R 4 is independently selected from alkyl, aryl, aralkyl, carbocyclyl, heterocyclyl, heteroaryl, carbocyclylalkyl, heterocyclylalkyl, or heteroarylalkyl;
R 5 is alkyl, alkenyl, alkynyl, aryl, aralkyl, carbocyclyl, heterocyclyl, heteroaryl, carbocyclylalkyl, heterocyclylalkyl, or heteroarylalkyl; and
n is an integer selected from 0, or 1.
2. The compound or pharmaceutical acceptable salt of claim 1 , wherein X is O.
3. The compound or pharmaceutical acceptable salt of claim 1 , wherein X is NR 5 .
4. The compound or pharmaceutical acceptable salt of claim 1 , wherein R 1 is hydrogen.
5. The compound or pharmaceutical acceptable salt of claim 1 , wherein R 1 is alkyl.
6. The compound or pharmaceutical acceptable salt of claim 1 , wherein R 5 is alkyl, carbocyclylalkyl, aralkyl, heterocyclylalkyl, or heteroarylalkyl.
7. The compound or pharmaceutical acceptable salt of claim 6 , wherein R 5 is alkyl, and the alkyl group is optionally substituted with hydroxy, halo, cyano, alkenyl, alkynyl, alkoxy, aryloxy, (alkoxy)alkoxy, aminoalkoxy, hydroxalkoxy, NH 2 , NHR 4 , N(R 4 ) 2 , NHC(O)R 4 , NHC(O)OR 4 , NHC(O)NHR 4 , NHC(O)N(R 4 ) 2 , NHS(O) 2 R 4 , NR 4 C(O)R 4 , NR 4 C(O)OR 4 , NR 4 C(O)NHR 4 , NR 4 C(O)N(R 4 ) 2 , NR 4 S(O) 2 R 4 , C(O)NHR 4 , C(O)N(R 4 ) 2 , C(O)R 4 , C(O)OR 4 , S(O) 2 R 4 , S(O) 2 NHR 4 , S(O) 2 N(R 4 ) 2 ; and
each R 4 is independently selected from alkyl, aryl, aralkyl, carbocyclyl, heterocyclyl, heteroaryl, carbocyclylalkyl, heterocyclylalkyl, or heteroarylalkyl.
8. The compound or pharmaceutical acceptable salt of claim 6 , wherein R 5 is carbocyclylalkyl, aralkyl, heterocyclylalkyl, or heteroarylalkyl.
9. The compound or pharmaceutical acceptable salt of claim 1 , wherein R 5 is alkenyl, or alkynyl.
10. The compound or pharmaceutical acceptable salt of claim 1 , wherein R 5 is carbocyclyl.
11. The compound or pharmaceutical acceptable salt of claim 1 , wherein R 5 is heterocyclyl.
12. The compound or pharmaceutical acceptable salt of claim 1 , wherein R 5 is aryl.
13. The compound or pharmaceutical acceptable salt of claim 1 , wherein R 5 is heteroaryl.
14. The compound or pharmaceutical acceptable salt of claim 1 , wherein n is 0.
15. The compound or pharmaceutical acceptable salt of claim 1 , wherein n is 1.
16. The compound or pharmaceutical acceptable salt of claim 1 , wherein R 3 is halogen, alkyl, or alkoxy.
17. A compound, or pharmaceutically acceptable salt thereof, chosen from:
18. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound as described in claim 1 , or a pharmaceutically acceptable salt thereof.
19. A method for treating cancer in subject comprising administering to the subject in need thereof a composition comprising a compound as described in claim 1 , or a pharmaceutically acceptable salt thereof.
20. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 17 , or a pharmaceutically acceptable salt thereof.
21. A method for treating cancer in subject comprising administering to the subject in need thereof a composition comprising a compound as described in claim 17 , or a pharmaceutically acceptable salt thereof.